The non-exclusive partnership will result in the integration of Ori’s proprietary CGT manufacturing platform’s data architecture with ATMPS’ Hataali, a secure data sharing platform, specially designed as a scalable system for advanced therapies.
The combination of the two proprietary platforms is aimed at providing improved product tracking, scheduling as well as live monitoring of the manufacturing status across the entire CGT supply chain from vein to vein, said the partners.
Ori said it selected ATMPS’ Hataali technology for integration with its platform to allow the secure sharing of relevant process data with therapy developers, contract development and manufacturing organizations (CDMOs) and even clinicians or patients in real-time.
We heard from Jason Foster, CEO, Ori Biotech and Raja Sharif, CEO, ATMPS, about the implications of the partnership for the sector.
BioPharma-Reporter: First off, can you tell us more about how Hataali works?
Raja Sharif: Hataali is a vein to vein, blockchain based, cell orchestration platform, providing full chain of custody, identity, and condition information. It allows multiple stakeholders – hospitals, manufacturers, couriers – to communicate and coordinate their activities in real time, thereby increasing efficiency, ensuring patient safety and regulatory compliance.
Hospitals can order and pay for multiple ATMPs through a single portal, while manufacturers can serve and schedule treatments for multiple sites worldwide with immutable data assurance.